Dupixent

Active substance

dupilumab

Holder

Sanofi Belgium

Status

Running

Indication

add-on therapy with intranasal corticosteroids for treatment of severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and comorbid asthma patients who have participated and exited the phase 4 clinical study EVEREST (LPS16747).

Public documents

Approbation

Information for the patient

Informed consent

Last update

22/12/2023

Last updated on 13/02/2024